Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.30 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21657581 | 0.98 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8014306 | 0.92 | MEN1 (0.58) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21068785 | 0.87 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1ALDH1A1 | |
| SCHEMBL23093249 | 0.85 | MEN1 (0.49) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL3030136 | 0.84 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1ALDH1A1 | |
| SCHEMBL30854404 | 0.84 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23930447 | 0.83 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6714850 | 0.82 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13455405 | 0.82 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL31255467 | 0.82 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638477-B | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-110637022-B | Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-2504327-B1 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ARISGEN SA (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2504327-B1 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ARISGEN SA (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-8624044-B2 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ARISGEN SA (CH) | 2014-01-07 | — | — | US | disclosed |
| US-8624044-B2 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ARISGEN SA (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120301401-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | ARISGEN SA (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120301401-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | ARISGEN SA (CH) | 2012-11-29 | — | — | US | disclosed |
| EP-2504327-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | ArisGen SA (CH) | 2012-10-03 | — | — | EP | disclosed |
| EP-2332929-A1 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ArisGen SA (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332929-A1 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ArisGen SA (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011064300-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | ARISGEN SA (CH) | 2011-06-03 | — | — | WO | disclosed |
| EP-1581535-B3 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1581535-B9 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-7317009-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| EP-1581535-B1 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1581535-A1 | PYRROLOPYRIDAZINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063197-A1 | PYRROLOPYRIDAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301401-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | OXER1, CBR3, CBR1 | MEN1 3657/4885KMT2A 2385/4885KDM4C 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.